AbbVie and BigHat Biosciences enter therapeutic research collaboration

AbbVie and BigHat Biosciences announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience. Working with AbbVie, BigHat will utilize its Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high quality antibodies for multiple therapeutic targets. Under the agreement, BigHat will receive an upfront payment of $30M and may be eligible to receive up to approximately $325M in aggregate research and development milestones, with potential for further commercial milestones as well as tiered royalties on net sales.